Corticosteroids for Treating Sepsis in Adult Patients: A Systematic Review and Meta-Analysis

Abstract

ObjectiveCorticosteroids are a common option used in sepsis treatment. However, the efficacy and potential risk of corticosteroids in septic patients have not been well assessed. This review was performed to assess the efficacy and safety of corticosteroids in patients with sepsis.MethodsPubMed, Embase, and Cochrane library databases were searched from inception to March 2021. Randomized controlled trials (RCTs) that evaluated the effect of corticosteroids on patients with sepsis were included. The quality of outcomes in the included articles was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation methodology. The data were pooled by using risk ratio (RR) and mean difference (MD). The random-effects model was used to evaluate the pooled MD or RR and 95% confidence intervals (CIs).ResultsFifty RCTs that included 12,304 patients with sepsis were identified. Corticosteroids were not associated with the mortality in 28-day (RR, 0.94; 95% CI, 0.87–1.02; evidence rank, moderate) and long-term mortality (>60 days) (RR, 0.96; 95% CI, 0.88–1.05) in patients with sepsis (evidence rank, low). However, corticosteroids may exert a significant effect on the mortality in the intensive care unit (ICU) (RR, 0.9; 95% CI, 0.83–0.97), in-hospital (RR, 0.9; 95% CI, 0.82–0.99; evidence rank, moderate) in patients with sepsis or septic shock (evidence rank, low). Furthermore, corticosteroids probably achieved a tiny reduction in the length of hospital stay and ICU. Corticosteroids were associated with a higher risk of hypernatremia and hyperglycemia; furthermore, they appear to have no significant effect on superinfection and gastroduodenal bleeding.ConclusionsCorticosteroids had no significant effect on the 28-day and long-term mortality; however, they decreased the ICU and hospital mortality. The findings suggest that the clinical corticosteroids may be an effective therapy for patients with sepsis during the short time.Systematic Review Registrationhttps://inplasy.com/wp-content/uploads/2021/05/INPLASY-Protocol-1074-4.pdf

Positive Effects of Neutrophil Elastase Inhibitor (Sivelestat) on Gut Microbiome and Metabolite Profiles of Septic Rats

“…Among these, cortisone, which has anti-inflammatory effects, was the most abundant differential metabolite. The latest Surviving Sepsis Campaign (SSC) guidelines recommend the use of corticosteroids in septic shock patients (moderate quality of evidence), and our latest meta-analysis also showed that corticosteroids improved intensive care unit and in-hospital survival (Evans et al, 2021;Liang et al, 2021), supporting the beneficial effects of corticosteroids in sepsis. Further, 6aminopenicillanic acid was the precursor of all semi-synthetic penicillin and could be introduced into different side chains to produce various antibiotics (Rolinson and Geddes, 2007).…”

Characteristics and outcomes of patients with sepsis who had cortisol level measurements or received hydrocortisone during their intensive care unit management: A retrospective single center study

“… 22 Recent systematic reviews and meta-analyses on the use of hydrocortisone in patients with sepsis and septic shock have provided disparate results. 5 , 23 , 24 …”

Treating COVID-19: Targeting the Host Response, Not the Virus

“…In the RECOVERY RCT, dexamethasone reduced 28-day mortality in patients receiving mechanical ventilation (MV; rate ratio = 0.64) and in those requiring oxygen treatment without MV (rate ratio = 0.82), but not in those who received no respiratory support (rate ratio = 1.19) [ 118 ]. These results were not surprising: steroid treatment had been tested previously (with mixed results) in patients with sepsis and ARDS [ 119 , 120 , 121 ]. In.…”